Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ivonescimab + nab-paclitaxel followed by spatially fractionated radiotherapy in advanced solid tumors
ChiCTR2400094961Phase 2Recruiting
- Sponsor
- Department of Oncology, Affiliated Hospital of Southwest Medical University
- Start
- Dec 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab and paclitaxel in Nonhematologic neoplasms, sponsored by Department of Oncology, Affiliated Hospital of Southwest Medical University. Primary endpoint: Objective response rate. Started Dec 2024; status: recruiting.
02
Drugs
ivonescimabpaclitaxel
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2400094961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094961.